Albany Molecular Research

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal) and Facebook (@AlbanyMolecularResearchInc).
Type
Public
HQ
Albany, US
Founded
1991
Size (employees)
2,220 (est)
Albany Molecular Research was founded in 1991 and is headquartered in Albany, US

Albany Molecular Research Office Locations

Albany Molecular Research has an office in Albany
Albany, US (HQ)
26 Corporate Cir

Albany Molecular Research Data and Metrics

Albany Molecular Research Financial Metrics

Albany Molecular Research's revenue was reported to be $163.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

163.8 m

Net income (Q1, 2017)

(10.7 m)

EBIT (Q1, 2017)

2.1 m

Market capitalization (17-Aug-2017)

928.3 m

Cash (31-Mar-2017)

35.2 m
Albany Molecular Research's current market capitalization is $928.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

246.6 m276.6 m402.4 m570.5 m

Revenue growth, %

12%45%42%

Operating expense total

226.4 m270.8 m388.7 m589.2 m

EBIT

20.2 m5.7 m13.6 m(18.8 m)

EBIT margin, %

8%2%3%(3%)

Interest expense

(1.3 m)(11 m)(19.4 m)(39.9 m)

Interest income

11 k3 k14 k(39.9 m)

Income tax expense

7 m(2.2 m)(1.2 m)10.2 m

Net Income

12.7 m(3.3 m)(2.3 m)(70.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

68.2 m62.5 m81.8 m89.5 m104.6 m105.6 m120.8 m152.7 m163.8 m

R&D expense

128 k568 k490 k384 k1.9 m3.2 m3.5 m4.6 m3.4 m

General and administrative expense

12.7 m11.6 m17.5 m16.5 m21.2 m24.6 m27.9 m37.3 m33.4 m

Operating expense total

12.9 m12.1 m18 m16.9 m23.1 m27.8 m31.4 m41.9 m36.8 m

EBIT

5.1 m(9.7 m)1.2 m6.2 m10 k(4.2 m)6.5 m(15.7 m)2.1 m

EBIT margin, %

7%(16%)2%7%0%(4%)5%(10%)1%

Interest expense

(3.1 m)(2.6 m)(3 m)(3.2 m)(6.3 m)(7.1 m)(7.1 m)(12.7 m)(12.8 m)

Pre tax profit

1.8 m(12.1 m)(1.3 m)3.6 m(5.5 m)(12.3 m)(6.3 m)(28.9 m)

Income tax expense

(1.9 m)(3.4 m)885 k1.3 m(1.3 m)(2.2 m)15 m(5.5 m)(850 k)

Net Income

3.7 m(8.6 m)(2.2 m)2.3 m(4.2 m)(10.1 m)(21.3 m)(23.4 m)(10.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

175.9 m47 m49.3 m52 m

Accounts Receivable

52.2 m71.6 m110.4 m144.8 m

Inventories

7.1 m11 m16.2 m167.1 m

Current Assets

279 m191 m280.2 m392.9 m

PP&E

127.8 m165.5 m209.5 m364.8 m

Goodwill

61.8 m169.5 m231.3 m

Total Assets

445.3 m520 m865.6 m1.2 b

Accounts Payable

24.2 m32.2 m60.9 m111.1 m

Total Debt

22.5 m

Current Liabilities

43.9 m48.7 m99.1 m175.5 m

Total Liabilities

910.7 m

Additional Paid-in Capital

235.8 m243.9 m296.3 m400.5 m

Retained Earnings

87.9 m79.6 m77.3 m7.2 m

Total Equity

240.8 m241.8 m287.2 m299 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0 x

Financial Leverage

1.8 x2.2 x3 x4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

130.4 m18.4 m28.5 m42.6 m79.5 m44.2 m30.7 m44.8 m35.2 m

Accounts Receivable

58.5 m56.2 m78.4 m79.1 m88.3 m96.1 m100.6 m126.9 m139.7 m

Inventories

44.3 m56 m53.5 m60.6 m104.7 m94.1 m93.2 m201.9 m174 m

Current Assets

260.8 m159 m189.8 m206.7 m303.4 m274 m256.7 m404.2 m385.2 m

PP&E

131.6 m165.9 m177 m175 m213.7 m216.9 m222 m376.1 m360.3 m

Goodwill

16.9 m62 m92.9 m94 m145.7 m172.9 m170.7 m241.4 m230.9 m

Total Assets

520.2 m533 m571.1 m602.6 m819.9 m834.2 m806.5 m1.3 b1.2 b

Accounts Payable

32.7 m41.1 m42.8 m49.5 m63.3 m73.7 m72.5 m127.4 m108.9 m

Current Liabilities

50.1 m54.6 m53.8 m60.6 m99.3 m101.6 m102.7 m182.5 m167 m

Additional Paid-in Capital

240.4 m242.4 m247.6 m250.7 m295.3 m300.9 m303.9 m398.3 m403.5 m

Retained Earnings

90.1 m81.5 m77.4 m79.7 m75.5 m67.3 m46 m22.6 m(3.5 m)

Total Equity

253.3 m245.2 m249 m288.7 m286.9 m262.9 m338 m296.8 m

Financial Leverage

2.1 x2.2 x2.4 x2.8 x2.9 x3.1 x3.7 x3.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

12.7 m(3.3 m)(2.3 m)(70.2 m)

Depreciation and Amortization

15.9 m18.4 m27 m50.6 m

Accounts Receivable

(10 m)(13 m)(9.4 m)(10.8 m)

Inventories

(5.1 m)(8 m)7.7 m21.5 m

Cash From Operating Activities

28.2 m1.9 m39.6 m26.6 m

Purchases of PP&E

(11.1 m)(17.2 m)(22 m)(51.4 m)

Cash From Investing Activities

(11.2 m)(163.3 m)(221.7 m)(193.2 m)

Long-term Borrowings

(775 k)(5.1 m)(81.9 m)(49 m)

Cash From Financing Activities

136.9 m33.2 m185.4 m170.8 m

Interest Paid

1.3 m3.5 m11.6 m21.4 m

Income Taxes Paid

3.4 m5.9 m8.2 m8.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

3.7 m(8.6 m)(2.2 m)2.3 m(4.2 m)(10.1 m)(21.3 m)(23.4 m)(10.7 m)

Accounts Receivable

79.1 m88.3 m96.1 m100.6 m126.9 m139.7 m

Inventories

60.6 m104.7 m94.1 m93.2 m201.9 m174 m

Accounts Payable

49.5 m63.3 m73.7 m72.5 m127.4 m108.9 m
USDY, 2017

Revenue/Employee

73.8 k

Financial Leverage

3.9 x

Albany Molecular Research Market Value History

Albany Molecular Research Revenue Breakdown

Albany Molecular Research Median Salaries

Source: 43 public H-1B filings from Albany Molecular Research

Traffic Overview of Albany Molecular Research

Albany Molecular Research Online and Social Media Presence

Albany Molecular Research Company Life and Culture

You may also be interested in